Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction

Department of Pathology and Division of Hematology-Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9073, USA.
Transfusion (Impact Factor: 3.23). 10/2009; 50(2):487-92. DOI: 10.1111/j.1537-2995.2009.02413.x
Source: PubMed


Plasma and platelets (PLTs) are often transfused to correct mild to moderately abnormal laboratory values. Our objective was to reduce unnecessary plasma and PLT transfusions to nonbleeding patients by prospective triage and education of end users in evidence-based hemostasis and transfusion medicine practices.
Using the Parkland Memorial Hospital's transfusion service and admission database as the data source, this study comprises the comparison of transfusion data on plasma and PLT use between pre- (2000-2002) and posttriage (2003-2006) periods. Yearly transfusion and wastage data on red blood cells (RBCs), plasma, and PLTs and yearly hospital admissions, trauma visits, and surgical procedures were extracted retrospectively for the study.
The study revealed that implementation of triage resulted in a significant reduction of plasma (60%) and PLT (25%) transfusions, saving more than $3,000,000 over 4 years.
Prospective triage and evidence-based transfusion practice education reduced unnecessary plasma and PLT transfusions and health care costs.

6 Reads
    • "After full texts were examined, 24 records [8–31] were judged to be eligible. Fourteen records excluded after examining full texts are shown in Supplementary Table S2 [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45]. Four conference abstracts were also published in full-article format [28] [29] [30] [31], and therefore, 20 unique studies were included in the review (Fig). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Decision support systems (DSSs) provide clinicians with tailored treatment recommendations by combining individual patient information and local guidelines. The objective of this systematic review was to assess the effects of electronic DSS on blood product ordering practices. Eligible studies were identified from searches of MEDLINE, Embase, CINAHL, The Cochrane Library, PubMed, and the Transfusion Evidence Library from January 2000 to April 2014. Of these, 23 articles were eligible, resulting in the inclusion of 20 independent studies in this systematic review. There was a significant variation in study population, the type of DSS used, and outcome reporting. All but one study used a before-after design without any element of randomization. Overall, there is good evidence that implementation of a DSS improves red blood cell usage. The effect of a DSS on plasma, platelets, and cryoprecipitate usage is less clear probably because fewer studies have been conducted focusing on these products. In addition, the introduction of a DSS resulted in cost savings in the 7 studies that reported financial outcomes. Patient outcomes were generally not studied in detail, and there were few data on the sustainability of the effect of DSS. Further data are needed to assess the effect of a DSS on blood products other than red blood cell, and future studies should standardize reporting of outcomes. Copyright © 2014 Elsevier Inc. All rights reserved.
    Transfusion Medicine Reviews 11/2014; 29(1). DOI:10.1016/j.tmrv.2014.10.002 · 2.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The majority of fresh-frozen plasma (FFP) is transfused in the United States in the management of acquired bleeding disorders. The prothrombin time (PT), and its derivative the international normalized ratio (INR), is the most common test used to detect the presence and gauge the severity of these disorders. Observation studies have shown that the PT correlates poorly with clinical bleeding and that transfusion of plasma often achieves no measurable change in the INR nor is of any known clinical benefit. Data on FFP and red blood cell transfusions and measures of hospital activity and mortality were collected over a 12-year period. The first 3 years were baseline years, the next 3 years were physician education years, and in the last 6 years all requests for FFP were screened. Orders were discouraged if the INR was less than 2.0 in the absence of active bleeding and the use of vitamin K was encouraged if the patient was taking warfarin. This program ultimately resulted in an approximate 80% reduction in transfused FFP using the average of the baseline years compared to the average of the last 3 years (157 ± 19 units FFP/1000 discharges vs. 30 ± 15, p < 0.01, respectively). Overall, hospital activity remained largely unchanged or increased. No unexpected bleeding was reported, which was attributed to a failure to transfuse FFP, and inpatient mortality rate decreased during these 12 years. A program of engagement and interdiction using evidence-based guidelines can successfully decrease the use of FFP without any observable increase in unexpected bleeding.
    Transfusion 10/2010; 51(4):754-61. DOI:10.1111/j.1537-2995.2010.02900.x · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three basic categories of hemostats are widely used in surgery today: chemical agents, thermal devices, and mechanical methods that use pressure or ligature to slow bleeding. Each has its benefits and limitations. However, nanotechnology is rapidly ushering in new medical technologies. This review focuses on the 'nanohemostat', a new class of hemostatic agent that stops bleeding in less than 15 seconds by using (RADA)4, referred to as nanohemostat-1 (NHS-1), a synthetic biological material that self-assembles at the nanoscale when applied to a wound, and compares it to the characteristics of the 'ideal hemostat'.
    Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 01/2011; 3(1):70-8. DOI:10.1002/wnan.110 · 4.49 Impact Factor
Show more